Leap Therapeutics, Inc. (LPTX) Stock Analysis

Leap Therapeutics, Inc. (LPTX) Healthcare & Pipeline Overview

Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies, primarily through its lead program DKN-01, a monoclonal antibody. With ongoing clinical trials across multiple cancer types and a strategic partnership with BeiGene, LPTX aims to address unmet needs in oncology.

What Is the Investment Thesis for LPTX?

Leap Therapeutics presents a high-risk, high-reward investment opportunity centered on the clinical development of DKN-01. The investment thesis hinges on the successful completion of ongoing clinical trials and the potential for DKN-01 to demonstrate efficacy across multiple cancer types. Key value drivers include positive clinical trial data readouts, expansion of DKN-01's application to new indications, and the continued strength of the partnership with BeiGene. The company's small market capitalization of $31.9M reflects the inherent risks associated with clinical-stage biopharmaceutical companies, including the potential for trial failures and regulatory hurdles. However, successful commercialization of DKN-01 could lead to significant upside potential. Investors should closely monitor clinical trial progress and regulatory milestones.

Based on FMP financials and quantitative analysis

LPTX Key Highlights

Lead program DKN-01 is in multiple ongoing clinical trials targeting esophagogastric, hepatobiliary, gynecologic, and prostate cancers.

• Strategic partnership with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand.
• Focus on DKK1 inhibition, a novel approach to cancer therapy.
• Relatively small market capitalization of $31.9M presents both risk and potential for high growth.
• Gross margin of -9631.6% reflects the company's stage as a research and development entity with limited product revenue.

Who Are LPTX's Competitors?

LPTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are LPTX's Key Strengths?

Novel DKK1 inhibition mechanism with DKN-01.

• Strategic partnership with BeiGene.
• Multiple ongoing clinical trials across various cancer types.

What Are LPTX's Weaknesses?

Reliance on a single lead program (DKN-01).

• Negative profit and gross margins.
• Small market capitalization and limited financial resources.

What Could Drive LPTX Stock Higher?

Data readouts from ongoing clinical trials of DKN-01 in esophagogastric cancer.

• Data readouts from ongoing clinical trials of DKN-01 in hepatobiliary cancer.
• Potential expansion of partnership with BeiGene to new territories.
• Enrollment and progress in ongoing clinical trials.

What Are the Key Risks for LPTX?

Financial-distress signal — its Altman Z-Score of 1.05 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-46.9%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays.
• Regulatory hurdles and delays in obtaining approvals.
• Competition from other cancer therapies.
• Dependence on the success of DKN-01.
• Limited financial resources and potential need for additional funding.

What Are the Growth Opportunities for LPTX?

• Expansion of DKN-01 into new cancer indications: Leap Therapeutics has the opportunity to expand the clinical development of DKN-01 into additional cancer types beyond its current focus. This could involve exploring DKN-01's efficacy in cancers with high DKK1 expression or in combination with other therapies. The global oncology market is projected to reach $536.67 billion by 2030, providing a significant market opportunity for successful new cancer therapies. Timeline: Ongoing clinical trials with potential readouts in the next 1-3 years.
• Advancement of combination therapies: Combining DKN-01 with other cancer treatments, such as chemotherapy or immunotherapy, could enhance its efficacy and broaden its applicability. This strategy could involve conducting clinical trials to evaluate the synergistic effects of DKN-01 with existing therapies. The market for combination cancer therapies is growing rapidly, driven by the increasing understanding of cancer biology and the development of new targeted agents. Timeline: Ongoing clinical trials with potential readouts in the next 1-2 years.
• Geographic expansion through partnerships: Leveraging its partnership with BeiGene, Leap Therapeutics can explore opportunities to expand its geographic reach beyond Asia. This could involve partnering with other pharmaceutical companies to develop and commercialize DKN-01 in other regions, such as Europe or North America. The global pharmaceutical market is highly fragmented, with significant regional variations in regulatory requirements and market access. Timeline: Potential for new partnerships in the next 2-3 years.
• Development of companion diagnostics: Developing companion diagnostics to identify patients who are most likely to respond to DKN-01 could improve its clinical efficacy and market adoption. This would involve identifying biomarkers that predict DKN-01 response and developing diagnostic tests to detect these biomarkers. The market for companion diagnostics is growing rapidly, driven by the increasing focus on personalized medicine. Timeline: Potential for development of companion diagnostics in the next 2-4 years.
• Acquisition or in-licensing of new assets: Leap Therapeutics could acquire or in-license new therapeutic assets to diversify its pipeline and reduce its reliance on DKN-01. This could involve acquiring companies or licensing technologies that complement its existing expertise in cancer therapy. The biotechnology industry is characterized by active M&A and licensing activity, with companies constantly seeking to expand their pipelines and capabilities. Timeline: Ongoing evaluation of potential acquisition and licensing opportunities.

What Are LPTX's Competitive Advantages?

• Proprietary DKN-01 antibody with potential for broad application in oncology.
• Strategic partnership with BeiGene provides access to resources and markets.
• Focus on DKK1 inhibition, a novel and potentially differentiated approach to cancer therapy.

What Does LPTX Do?

Leap Therapeutics, Inc., founded in 2011 and based in Cambridge, Massachusetts, is a biopharmaceutical company dedicated to acquiring and developing innovative therapies for cancer treatment. Originally incorporated as HealthCare Pharmaceuticals, Inc., the company rebranded as Leap Therapeutics, Inc. in November 2015, signaling a strategic shift towards novel therapeutic approaches. The company's primary focus is on its lead clinical-stage program, DKN-01, a humanized monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is a protein implicated in tumor growth and metastasis, making it a promising target for cancer therapy. DKN-01 is currently undergoing multiple clinical trials, both as a monotherapy and in combination with other treatments, targeting a range of cancers, including esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics has a strategic collaboration with BeiGene, Ltd., granting BeiGene exclusive rights to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand, providing Leap with significant financial and development resources.

What Products and Services Does LPTX Offer?

• Acquires and develops therapies for the treatment of cancer.
• Focuses on its lead clinical-stage program, DKN-01.
• DKN-01 is a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1).
• Conducts clinical trials for DKN-01 in various cancer types.
• Targets esophagogastric, hepatobiliary, gynecologic, and prostate cancers.
• Collaborates with BeiGene, Ltd. for development and commercialization in Asia (excluding Japan), Australia, and New Zealand.

How Does LPTX Make Money?

• Develops and out-licenses novel cancer therapies.
• Generates revenue through licensing agreements and potential future product sales.
• Focuses on clinical development and seeks partnerships for commercialization.

What Industry Does LPTX Operate In?

Leap Therapeutics operates within the competitive biotechnology industry, characterized by high R&D costs, lengthy development timelines, and significant regulatory hurdles. The oncology market, in particular, is a major area of focus, driven by the increasing prevalence of cancer globally. Companies like Leap are striving to develop novel therapies that address unmet needs in cancer treatment. The industry is marked by intense competition, with both large pharmaceutical companies and smaller biotechs vying for market share. Strategic partnerships and collaborations are common, as companies seek to share the risks and costs associated with drug development.

Who Are LPTX's Key Customers?

• Pharmaceutical companies (e.g., BeiGene) through licensing agreements.
• Future patients who may benefit from DKN-01.
• Healthcare providers who will prescribe DKN-01 if approved.

Wall Street analysts project Leap Therapeutics, Inc. revenue of about $6.0M for fiscal 2026, with EPS near $-0.53.

Leap Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.05 places it in the distress zone, a signal of elevated financial risk.

Return on equity for Leap Therapeutics, Inc. stands at -46.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -65.1%, showing how much profit it generates from its asset base. A current ratio of 27.28 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -50.6%, the inverse of the P/E and a quick read on earnings relative to price.

Leap Therapeutics, Inc. (LPTX) Valuation Context

Valued at $31.9M, LPTX is classified as a micro-cap stock.

Company Profile

Leap Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO Douglas E. Onsi. LPTX has traded publicly since 2017.

LPTX Financials

LPTX Latest News

Common Questions About LPTX (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources